The state of California currently has 940 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
NCT06228482
Recruiting
This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Nonsmall Cell Lung Cancer
Register for Updates
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425
Recruiting
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: City of Hope, Duarte, California
Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Register for Updates
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT04349501
Recruiting
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called Restriction Spectrum Imaging (RSI-MRI) to evaluate whether RSI-MRI can predict treatment response.
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: UCSD Moores Cancer Center, La Jolla, California
Conditions: Prostate Cancer
Register for Updates
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947
Recruiting
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of California Davis, Sacramento, California
Conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT04333706
Recruiting
This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locally advanced TNBC are at high risk of developing lethal metastatic disease within 2 years of diagnosis, especially for those without a pathologic complete response (pCR) after neoadjuvant chemotherapy. The high risk occurs... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Register for Updates
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT01034033
Recruiting
The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Ovarian Cancer, Gynecologic Cancers, Ovarian/Peritoneal/Fallopian Cancer
Register for Updates
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +1 locations
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
NCT04324294
Recruiting
The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Pancreatitis, Pancreas Cancer, Pancreas Cyst
Register for Updates
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
NCT04372524
Recruiting
This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant. By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aim... Read More
Gender:
All
Ages:
Between 0 years and 24 years
Trial Updated:
12/02/2023
Locations: University of California San Francisco, San Francisco, California
Conditions: Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Register for Updates
IS-002 in Prostate Cancer
NCT05946603
Recruiting
Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostatectomy (RARP) with (extended) pelvic lymph node dissection ((e)PLND) using the da Vinci® X/Xi Surgical System with Firefly® Fluorescence Imaging.
Gender:
Male
Ages:
Between 18 years and 75 years
Trial Updated:
12/01/2023
Locations: UCSF, San Francisco, California
Conditions: Prostate Cancer
Register for Updates
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT02935205
Recruiting
This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has spread from where it started to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androg... Read More
Gender:
Male
Ages:
19 years and above
Trial Updated:
11/28/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Register for Updates
ExoLuminate Study for Early Detection of Pancreatic Cancer
NCT05625529
Recruiting
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performan... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: University of California, San Diego, La Jolla, California +3 locations
Conditions: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Register for Updates